AA-amyloidosis caused by visceral leishmaniasis in a human immunodeficiency virus-infected patient.

Détails

ID Serval
serval:BIB_16F420BDB2DF
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Etude de cas (case report): rapporte une observation et la commente brièvement.
Collection
Publications
Institution
Titre
AA-amyloidosis caused by visceral leishmaniasis in a human immunodeficiency virus-infected patient.
Périodique
American Journal of Tropical Medicine and Hygiene
Auteur⸱e⸱s
de Vallière S., Mary C., Joneberg J.E., Rotman S., Bullani R., Greub G., Gillmore J.D., Buffet P.A., Tarr P.E.
ISSN
1476-1645[electronic]
Statut éditorial
Publié
Date de publication
2009
Volume
81
Numéro
2
Pages
209-12
Langue
anglais
Notes
Publication types: Case Reports ; Journal Article
Résumé
AA-amyloidosis in the setting of chronic visceral leishmaniasis (VL) has been reported in animal models but documentation in humans is unavailable. Here, we report on a Portuguese man who in 1996 was diagnosed with both human immunodeficiency virus (HIV)-infection and VL. Antiretroviral treatment led to sustained suppression of HIV viremia but CD4+ lymphocytes rose from 8 to only 160 cells/mL. Several courses of antimony treatment did not prevent VL relapses. Renal failure developed in 2006 and renal biopsy revealed AA-amyloidosis. The patient had cryoglobulinemia and serum immune complexes containing antibodies directed against seven leishmanial antigens. Antimony plus amphotericin B, followed by oral miltefosine resulted in a sustained VL treatment response with elimination of circulating Leishmania infantum DNA and CD4+ recovery. The concomitant reduction of serum AA levels and disappearance of circulating leishmanial immune complexes suggests that prolonged VL may lead to AA-amyloidosis in immunocompromised humans.
Mots-clé
Amphotericin B/therapeutic use, Amyloidosis/complications, Anti-HIV Agents/therapeutic use, Antiprotozoal Agents/therapeutic use, HIV Infections/complications, HIV Infections/drug therapy, Humans, Leishmaniasis, Visceral/complications, Leishmaniasis, Visceral/drug therapy, Male, Meglumine/therapeutic use, Organometallic Compounds/therapeutic use, Young Adult
Pubmed
Web of science
Création de la notice
01/10/2009 10:16
Dernière modification de la notice
20/08/2019 13:46
Données d'usage